欧洲疾控中心：ECDC研究疫苗对严重急性呼吸道感染实验室确诊严重急性呼吸系统综合征冠状病毒2型或季节性流感4.0版住院有效性的核心方案报告（英文版）

The end of 2019 saw the emergence of a novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing coronavirus disease 2019 (COVID-19). As of September 2024, more than 280 million cases and almost 2.3 million deaths had been reported in the WHO European Region [1]. As of July 2024, five vaccines (Comirnaty, Nuvaxovid [previously Novavax], Spikevax [previously COVID-19 vaccine Moderna], Jcovden [previously Covid-19 Vaccine Janssen], and Bimervax [previously COVID-19 Vaccine HIPR